NeoGenomics Inc (NEO) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of NeoGenomics Inc stock $13.28, price $15.25, that is 12.9% below the price, quality 44 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
NeoGenomics Inc
NEO · USExpensive (fair value 13% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $4.84 – $52.52 · fair‑value band $9.96 – $16.60 · the $15.25 price screens above the $13.28 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether NeoGenomics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Show moreShow less
It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.
In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization.
The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Stock analysis
NeoGenomics Inc (NEO) currently trades at $15.25, while our estimate is $13.28, 13% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $9.96 (bear) to $16.60 (bull), the price of $15.25 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
NeoGenomics Inc reported revenue of $727M in FY2025 versus $484M in FY2021, a compound +10.7%/yr. Reported net income was −$108M in FY2025.
Key figures
Market cap $2.0B · P/S ratio 3.02 · EPS (TTM) $−0.4100 · Net margin −6.8% · Return on equity −6.3% · Return on assets (EBIT) −6.5% (5-year average) · Operating margin −4.8% · Revenue (TTM) $766M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (medium confidence).
What moves the price
The share trades about 23% below its 52-week high and 112% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −13%, NEO screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 2 officers or directors sold shares worth $440,224 and none bought.
- SaleGreg D AunanChief Accounting Officer20,000 shares at $16.07$321,400Aug 4, 2026
- SaleLynn A. TetraultDirector2× since Jun 9, 2026: 10,614 shares, avg. $11.20$118,824Jun 15, 202610b5-1 plan
- SaleWarren StonePres & Chief Operating Officer22,128 shares at $12.50$276,600Jan 20, 202610b5-1 plan
- SaleAlicia C OlivoEVP, GC & Business Development20,916 shares at $12.00$250,992Nov 25, 202510b5-1 plan
Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 17, 2026. All filings at the SEC ↗
Revenue & earnings trend
NEO screens overvalued: fair value 13% below the price. Compare with Thermo Fisher Scientific Inc →
Compare NeoGenomics Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 151 stocks
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Quality Score by industry
- Return on equity by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| IQVIA Holdings IQV | $257.60 | $291.63 | +13% | vs NEO |
| WuXi AppTec Co 603259 | ¥146.07 | ¥164.66 | +13% | vs NEO |
| Illumina, Inc ILMN | $202.61 | $227.71 | +12% | vs NEO |
| Thermo Fisher Scientific Inc TMO | $686.79 | $686.04 | +0% | vs NEO |
| Danaher Corporation DHR | $225.77 | $209.18 | −7% | vs NEO |
| IDEXX Laboratories, Inc IDXX | $690.24 | $496.48 | −28% | vs NEO |
| Lonza Group LONN | CHF 663.00 | CHF 259.80 | −61% | vs NEO |
| Mettler-Toledo International Inc MTD | $1,713 | $655.06 | −62% | vs NEO |
| Agilent Technologies, Inc A | $172.22 | $64.20 | −63% | vs NEO |
| Waters Corporation WAT | $449.78 | $91.26 | −80% | vs NEO |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is NeoGenomics Inc (NEO) overvalued or undervalued?
What is the fair value of NEO?
What is the quality score of NEO?
What is the price target for NeoGenomics Inc (NEO)?
What is the NeoGenomics Inc stock forecast for 2026?
What is the revenue of NeoGenomics Inc (NEO)?
What is the intrinsic value of NeoGenomics Inc (NEO)?
Is NeoGenomics Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of NEO?
How much is NeoGenomics Inc worth?
What do the bullish and bearish scenarios say about NEO?
What is the PEG ratio of NEO?
How solid is the balance sheet of NeoGenomics Inc (NEO)?
How far is NEO from its 52-week high?
Which stocks are comparable to NeoGenomics Inc?
Is NeoGenomics Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of NeoGenomics Inc (NEO)?
What should I pay attention to with NeoGenomics Inc right now?
Key figures of NeoGenomics Inc
How large is the market capitalisation of NeoGenomics Inc (NEO)?
What is the P/S ratio of NeoGenomics Inc (NEO)?
What are the earnings per share of NeoGenomics Inc (NEO)?
What is the net margin of NeoGenomics Inc (NEO)?
What is the return on equity of NeoGenomics Inc (NEO)?
What is the EBIT return on assets of NeoGenomics Inc (NEO)?
What is the operating margin of NeoGenomics Inc (NEO)?
How fast is revenue growing at NeoGenomics Inc (NEO)?
How fast are earnings growing at NeoGenomics Inc (NEO)?
How much free cash flow does NeoGenomics Inc (NEO) generate?
How much net debt does NeoGenomics Inc (NEO) carry?
Watch NeoGenomics Inc in the live analysis
One click puts NeoGenomics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.